id: PW:0001135 rgd_url: https://rgd.mcw.edu/rgdweb/pathway/pathwayRecord.html?processType=view&species=Rat&acc_id=PW:0001135 title: parathyroid hormone signaling pathway description: 'The signaling initiated by the parathyroid hormone (PTH) plays a central role in calcium (Ca2+) and phosphate homeostasis. In response to low Ca2+, the hormone is secreted from the parathyroid glands; high Ca2+ levels activate the Ca2+ sensing receptor whose signaling inhibits its secretion. In the kidney, PTH regulates Ca2+ and phosphate reabsorption: specifically, it increases Ca2+ reabsorption leading to increased release of the metal into the circulation; it diminishes phosphate absorptionleading to excretion of the mineral. It exerts both catabolic and anabolic effects on bone; the former leads to Ca2+ and phosphate release while the latter renders the hormone an anti-osteoporosis agent. PTH also promotes production of the active form of vitamin D3 which leads to increase in circulating Ca2+, hence the negative effect vitamin D3 has on PTH activity. In the renal epithelial cells, the vanilloid transient potential receptor TRP5 and TRP6 are involved in Ca2+ influx and under the control of PTH and vitamin D. Upon entry, the metal ion is sequestered by calbindin buffers and then extruded through the concerted action of transporters such as PMCA1 and NCX1. PTH employs a G-protein coupled receptor (GPCR) that belongs to the B group: the parathyroid hormone receptor 1 (Pthr1). The related parathyroid hormone-like hormone (PTHrP), also signals via Pth1 but promotes distinct effects. The crystal structure of the extracellular domain (ECD) of Pth1r in complex with PTH has been solved; the PTH alpha helix is sandwiched within a hydrophobic groove formed by a three-layer alpha-beta-beta/alpha ECD fold click to access the structure page . The binding of PTH to Pth1r triggers conformational changes promoting coupling to heterotrimeric G proteins for which the receptor acts as a GTP exchange factor (GEF) catalyzing the exchange of GDP bound to the G alpha subunit, for GTP. The active, GTP-bound G alpha subunit can now dissociate from the complex to interact with its effectors; the G alpha will signal for as long as it is associated with GTP. Pthr1 couples to two types of G protein mediated signaling: the Galphas mediated signaling which promotes cAMP synthesis and further activates the protein kinase A (PKA) pathway and it appears to be the main downstream route, and the Galphaq mediated signaling which activates phospholipase C resulting in production of IP3 which triggers Ca2+ release from intracellular stores and DAG which activates the protein kinase C (PKC) pathway. G protein specific kinases such as Adrbk1 (Grk2) phosphorylate the receptor prompting its recognition by beta-arrestin proteins resulting in receptor desensitization and subsequent internalization; beta-arrestin bound receptors are sterically precluded from coupling to G proteins. In the case of PTH signaling, beta-arrestins may provide scaffolding functions and the same might be true for the beta/gamma dimers of heterotrimeric G proteins. It is believed that the beta/gamma dimers which interact with Pth1r, do not dissociate and instead allow for the interaction of the receptor with other partners. The intracellular tail of the receptor offers many binding sites; partners include calpain, calmodulin, the light chain subunit of the cytoplasmic dynein complex Dynlt1 but the role these interactions play in vivo is still to be determined. Important partners for Pth1r are the scaffolding proteins Slc9a3r known as the NHERF family of regulators of sodium/phosphate co-transporters type 2. The regulators contain two tandem N-terminal PDZ domains . Pth1r preferentially binds to the PDZ1 domain of Slc9a3r1 (NHERF1) and to the PDZ2 domain of Slc9a3r2 (NHE RF2). The interaction biases the receptor between the two G-protein mediated pathways promoting the Galphaq and, depending on the identity of the regulator, either inhibiting or having no effect on Galphas. The function of type 2 sodium/phosphate co-transporters is regulated by correct membrane targeting and retrieval/endocytosis. Ezrin, a FERM domain containing scaffold interacts with both Pth1r and Slc9a3r1; the ezrin-Slc3a9r1 scaffold is important for both the correct membrane targeting and for the Pth/Pth1r mediated endocytosis of Slc34a1 transporter, known as Npt2a. Ezrin is an AKAP (A kinase anchor protein) for PKA pathway. Activation of PKA and phosphorylation of Slc9a3r1 promotes disassembly of a ternary Slc34a1-Slc9a3r1-ezrin complex with subsequent internalization and degradation of the transporter. The effect of PTH on phosphate reabsorption is very fast; a similar, but rather slow response is elicited by the fibroblast growth factor 23 signaling. FGF23 also negatively regulates PTH and vitamin D3 production. An intricate interaction between PTH, vitamin D3 and FGF23 pathways underlies calcium and/or phosphate homeostasis.' diagram_image: https://rgd.mcw.edu/pathway/PW0001135/parathyroid%20hormone%20signaling%20pathway/pwmap.png pathway_studio_file: https://rgd.mcw.edu/pathway/PW0001135/parathyroid%20hormone%20signaling%20pathway/parathyroid%20hormone%20signaling%20pathway.gpp diagram_pathway_links: - id: PW:0000227 label: G protein mediated signaling pathway via Galphas family - id: PW:0000229 label: G protein mediated signaling pathway via Galphaq family - id: PW:0000543 label: protein kinase A (PKA) signaling pathway - id: PW:0000840 label: protein kinase C (PKC) signaling pathway - id: PW:0001141 label: calcium signaling pathway via the calcium-sensing receptor - id: PW:0001183 label: phosphate transport pathway diagram_gene_links: - id: RGD:2062 label: Adrbk1 - id: RGD:2156 label: Arrb1 - id: RGD:2157 label: Arrb2 - id: RGD:621161 label: Ezr - id: RGD:3440 label: Pth - id: RGD:3442 label: Pth1r - id: RGD:3708 label: Slc34a1 - id: RGD:708538 label: Slc9a3r1 - id: RGD:620380 label: Slc9a3r2 diagram_chemicals: - id: CHEBI:29108 label: Ca2+ - id: PUBCHEM.COMPOUND:6076 label: cAMP - id: PUBCHEM.COMPOUND:6026790 label: DAG - id: CHEBI:16595 label: IP3 diagram_edges: - source: Adrbk1 relation: negatively_affects target: Pth1r - source: Arrb1 relation: associated_with target: Pth1r - source: Arrb2 relation: associated_with target: Pth1r - source: Ezr relation: associated_with target: Pth1r - source: Ezr relation: associated_with target: Slc9a3r1 - source: G protein mediated signaling pathway via Galphaq family relation: positively_affects target: increased DAG/IP3 via PLC activation - source: G protein mediated signaling pathway via Galphas family relation: positively_affects target: activation of adenylyl cyclases/increased cAMP - source: Pth relation: associated_with target: Pth1r - source: Pth relation: negatively_affects target: phosphate reabsoprtion - source: Pth relation: negatively_affects target: phosphate transport pathway - source: Pth relation: positively_affects target: anabolic, catabolic effects on bone - source: Pth1r relation: associated_with target: Pth1r partners - source: Pth1r relation: associated_with target: Slc9a3r1 - source: Pth1r relation: associated_with target: Slc9a3r2 - source: Slc34a1 relation: associated_with target: Slc9a3r1 - source: calcium signaling pathway via the calcium-sensing receptor relation: negatively_affects target: Pth diagram_labels: - activation of adenylyl cyclases/increased cAMP - activation of adenylyl cyclases/increased cAMP --+> protein kinase A (PKA) signaling pathway - anabolic, catabolic effects on bone - Ca2+ --+> calcium signaling pathway via the calcium-sensing receptor - Ca2+ --+> Pth - Ca2+ reabsorption - increased DAG/IP3 via PLC activation - increased DAG/IP3 via PLC activation --+> protein kinase C (PKC) signaling pathway - phosphate reabsoprtion - Pth --+> Ca2+ reabsorption - Pth1r --+> G protein mediated signaling pathway via Galphaq family - Pth1r --+> G protein mediated signaling pathway via Galphas family diagram_other_links: - href: /wg/home/pathway2/molecular-pathways2/pth1r-partners label: Pth1r partners references: - id: RGD:7207465 citation: Mahon MJ Curr Drug Targets. 2012 Jan;13(1):116-28. - id: RGD:7207469 citation: 'Vilardaga JP, etal., Cell Mol Life Sci. 2011 Jan;68(1):1-13. doi: 10.1007/s00018-010-0465-9. Epub 2010 Aug 12.' - id: RGD:7207470 citation: 'Lee M and Partridge NC, Curr Opin Nephrol Hypertens. 2009 Jul;18(4):298-302. doi: 10.1097/MNH.0b013e32832c2264.' - id: RGD:7207819 citation: 'Prie D, etal., Horm Res Paediatr. 2011;76 Suppl 1:71-5. doi: 10.1159/000329175. Epub 2011 Jul 21.' - id: RGD:7207828 citation: 'Vilardaga JP, etal., Trends Pharmacol Sci. 2012 Aug;33(8):423-31. doi: 10.1016/j.tips.2012.05.004. Epub 2012 Jun 16.' - id: RGD:7207829 citation: 'Danks JA, etal., Gen Comp Endocrinol. 2011 Jan 1;170(1):79-91. doi: 10.1016/j.ygcen.2010.10.023. Epub 2010 Nov 11.' - id: RGD:7207830 citation: 'Pal K, etal., Acta Pharmacol Sin. 2012 Mar;33(3):300-11. doi: 10.1038/aps.2011.170. Epub 2012 Jan 23.' - id: RGD:7207832 citation: 'Pioszak AA and Xu HE, Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5034-9. doi: 10.1073/pnas.0801027105. Epub 2008 Mar 28.' - id: RGD:7207833 citation: 'Wang B, etal., J Biol Chem. 2012 Jul 13;287(29):24148-63. doi: 10.1074/jbc.M112.369405. Epub 2012 May 24.' - id: RGD:7207834 citation: 'Taylor CW and Tovey SC, Biochem Soc Trans. 2012 Feb;40(1):147-52. doi: 10.1042/BST20110615.' - id: RGD:7207835 citation: 'Boros S, etal., Pflugers Arch. 2009 May;458(1):99-109. doi: 10.1007/s00424-008-0602-6. Epub 2008 Nov 7.' - id: RGD:7207836 citation: Schoeber JP, etal., Biochem Soc Trans. 2007 Feb;35(Pt 1):115-9. - id: RGD:7207837 citation: 'Penido MG and Alon US, Pediatr Nephrol. 2012 Nov;27(11):2039-48. doi: 10.1007/s00467-012-2175-z. Epub 2012 May 3.'